共 150 条
[1]
Siegel RL(2023)Cancer statistics, 2023 CA A Cancer J Clin 73 17-48
[2]
Miller KA(2020)Epidemiology of renal cell carcinoma World J Oncol 11 79-87
[3]
Wagle NS(2005)Randomized phase III trial of high-dose interleukin-2 versus subcutaneous ınterleukin-2 and interferon in patients with metastatic renal cell carcinoma J Clin Oncol 23 133-141
[4]
Jemal A(2013)Pazopanib versus sunitinib in metastatic renal-cell carcinoma N Engl J Med 369 722-731
[5]
Padala SA(2016)Mechanisms and regulation of endothelial VEGF receptor signalling Nat Rev Mol Cell Biol 17 611-625
[6]
Barsouk A(2008)Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis ınhibitor Clin Cancer Res 14 3470-3476
[7]
Thandra KC(2005)Biology and clinical development of vascular endothelial growth factor–targeted therapy in renal cell carcinoma J Clin Oncol 23 1028-1043
[8]
Saginala K(2011)Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 763-773
[9]
Mohammed A(2007)Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition Nat Rev Cancer 7 475-485
[10]
Vakiti A(2022)Risk Factors for the Comorbidity of Hypertension and Renal Cell Carcinoma in the Cardio-Oncologic Era and Treatment for Tumor-Induced Hypertension Front Cardiovasc Med 9 810262-161